<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599076</url>
  </required_header>
  <id_info>
    <org_study_id>1R44NS103648-01</org_study_id>
    <nct_id>NCT03599076</nct_id>
  </id_info>
  <brief_title>Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease</brief_title>
  <official_title>Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioSensics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioSensics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal means of measuring motor impairment in Huntington disease (HD) is the Unified
      Huntington's Disease Rating Scale (UHDRS) total motor score, which is subjective,
      categorical, requires significant training to administer correctly, and only captures
      impairments in clinic. In this Direct to Phase II SBIR we will develop a wearable sensor
      system for objective, sensitive, and continuous assessment of Huntington's chorea during
      activities of daily living. The developed technology could be used clinically to detect
      changes in motor function in response to medications, or could be used scientifically to
      expedite and reduce the cost of early stage pharmaceutical clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chorea severity score</measure>
    <time_frame>12 months</time_frame>
    <description>Remotely monitored chorea severity score based on movement data during activities of daily living</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Manifest HD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Premanifest HD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HD Wear</intervention_name>
    <description>Wearable sensor system for monitoring Huntington's chorea during activities of daily living</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Manifest HD</arm_group_label>
    <arm_group_label>Premanifest HD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Huntington's Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CAG expansion â‰¥ 36

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joseph Gwin, PhD</last_name>
    <phone>888-589-6213</phone>
    <email>info@biosensics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Adams, MD</last_name>
      <phone>585-276-6825</phone>
      <email>Jamie_Adams@urmc.rochester.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

